01—Abstract
Summary
Summary of the 10-K filed February 13, 2020. Cited figures are marked; the original filing is the authoritative source.
Zoetis Inc.'s 2019 10-K report details a robust year of growth and strategic development in the animal health sector.
The company demonstrated strong revenue performance, driven by both its established product lines and new product introductions, particularly in the companion animal segment. Key acquisitions, such as Abaxis, were integrated, contributing to expanded diagnostic capabilities and overall revenue. Zoetis continues to invest significantly in research and development, focusing on product lifecycle innovation and novel solutions for both livestock and companion animals.
The company operates across two main segments: the U.S. and International, with each contributing significantly to overall revenue. Zoetis maintains a diversified product portfolio addressing a wide range of animal health needs, from vaccines and parasiticides to anti-infectives and diagnostics. The company's financial health appears solid, with consistent revenue growth and effective management of expenses, though it faces ongoing competitive pressures and the lifecycle management of key products.
Investors can find confidence in Zoetis's market leadership, commitment to innovation, and strong financial discipline. The company's focus on expanding its product offerings, entering new markets, and enhancing customer experience positions it well for continued growth in the dynamic animal health industry. Key risks include patent expirations, competition, regulatory changes, and global economic uncertainties, all of which are actively managed by the company.
02—Key points
Key Highlights
- Zoetis reported strong revenue growth in 2019, with a total of $6.26 billion, representing a 7% increase over 2018, driven by operational growth of 10%.
- The companion animal segment experienced significant growth, with revenue up 20% to $3.15 billion, driven by key dermatology products like Apoquel and Cytopoint, and advancements in parasiticides.
- The acquisition of Abaxis in July 2018 was integrated, contributing to expanded diagnostic offerings and revenue, particularly in the U.S. companion animal segment.
- Research and Development (R&D) expenses increased by 6% to $457 million, reflecting continued investment in innovation and product lifecycle management, supporting a pipeline of new and improved animal health solutions.
- The company generated robust net income of $1.5 billion, with diluted earnings per share of $3.11, showcasing effective cost management and operational efficiency.
- Zoetis returned significant capital to shareholders through share repurchases, completing a $1.5 billion program and having $1.7 billion remaining under a new authorization as of December 31, 2019, alongside dividend payments.
- The company's diverse product portfolio and global operational footprint across two segments (U.S. and International) provide stability, with international revenue growing 3% to $2.97 billion.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2019filed February 13, 2020Financial Statements
FY2019 against FY2018
| Line item | FY2019FY2018 | Change |
|---|---|---|
| Revenue | $6.26B$5.83B | +7.5% |
| Cost of Revenue | $1.99B$1.91B | +4.2% |
| Gross Profit | $4.27B$3.91B | +9.0% |
| SG&A Expenses | $1.64B$1.48B | +10.4% |
| Interest Expense | $223.00M$206.00M | +8.3% |
| Net Income | $1.50B$1.42B | +5.3% |
| EPS (Basic) | $3.14$2.96 | +6.1% |
| EPS (Diluted) | $3.11$2.93 | +6.1% |
| Shares Outstanding (Basic) | 478.13M483.06M | −1.0% |
| Shares Outstanding (Diluted) | 481.79M486.90M | −1.0% |
05—Questions
Frequently Asked Questions
What were Zoetis's primary revenue drivers in 2019?
Zoetis's primary revenue drivers in 2019 were its companion animal products, which saw a significant 20% increase in revenue to $3.15 billion, fueled by strong performance in dermatology products (like Apoquel and Cytopoint) and parasiticides. The U.S. segment also showed robust growth, up 11% to $3.20 billion. Livestock products experienced a slight decline of 4% to $3.03 billion, impacted by sector-specific challenges and distributor purchasing patterns, though poultry showed growth.
How did acquisitions impact Zoetis's financial performance in 2019?
The acquisition of Abaxis in July 2018 had a notable impact, contributing to revenue growth and strengthening Zoetis's position in the animal health diagnostics market. The integration of Abaxis enhanced the company's diagnostic portfolio and contributed to the strong performance of the U.S. companion animal segment. Other smaller acquisitions in 2019, like Platinum Performance and Phoenix Lab/ZNLabs, further diversified offerings in nutrition and diagnostics, respectively.
What are the key risks and challenges facing Zoetis, as outlined in the report?
Zoetis faces several risks, including potential safety or efficacy concerns with its products, the impact of generic competition as key product patents expire (such as Draxxin and Revolution/Stronghold), intense competition within the animal health industry, and the potential for disruptive innovations. Additionally, changes in distribution channels for companion animal products, regulatory changes, global economic conditions, foreign exchange rate fluctuations, and manufacturing or supply chain disruptions are also identified as significant risks.
How is Zoetis investing in future growth?
Zoetis is investing in future growth through several strategic initiatives. These include driving innovative growth by developing new products and lifecycle innovations across vaccines, pharmaceuticals, and diagnostics; enhancing customer experience through improved engagement; leading in digital and data analytics; cultivating a high-performing organization; and championing a healthier, more sustainable future. The company's R&D spending, which increased to $457 million in 2019, is a core component of this strategy.
06—Continue